Physician profile
Chi Tang
NPI 1013263870
$5,787.65
in general payments reported to CMS, 2019-2025
48 companies · $969 in 2025
The $969 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,715 · 2020: $390 · 2021: $304 · 2022: $918 · 2023: $699 · 2024: $792 · 2025: $969.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,418 · Education: $41.67.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,417.97 |
| Education | $41.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $750.61 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Amgen INC. | $558.95 | 2019-2025 | Evenity, Repatha, Prolia |
| Novo Nordisk INC | $553.86 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| Boehringer Ingelheim Pharmaceuticals, INC. | $423.74 | 2019-2025 | Jardiance |
| Amneal Pharmaceuticals LLC | $327.32 | 2019-2025 | Unithroid |
| Sanofi-Aventis U.S. LLC | $231.25 | 2019-2025 | |
| Abbott Laboratories | $225.06 | 2022-2025 | Freestyle Libre 3 |
| Astrazeneca Pharmaceuticals LP | $211.44 | 2019-2023 | Farxiga |
| Abbvie INC. | $199.51 | 2019-2025 | |
| Radius Health, INC. | $194.31 | 2019-2025 | Tymlos |
| Xeris Pharmaceuticals, INC. | $162.77 | 2022-2025 | Gvoke Hypopen, Recorlev |
| Medtronic Minimed, INC. | $156.91 | 2019 | |
| Antares Pharma, INC. | $132.65 | 2023-2025 | Xyosted, Nocdurna, Tlando |
| Merck Sharp & Dohme LLC | $126.68 | 2019-2020 | |
| Corcept Therapeutics | $126.53 | 2019-2024 | Korlym |
Show all 47 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $124.00 | 2021-2025 | Minimed 780g |
| Insulet Corporation | $123.57 | 2019-2025 | Omnipod |
| Cequr Corporation | $114.47 | 2022-2025 | Cequr Simplicity |
| Tandem Diabetes Care, INC. | $89.32 | 2019-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Amphastar Pharmaceuticals, INC. | $85.22 | 2024-2025 | Baqsimi |
| Ibsa Pharma INC. | $80.57 | 2019-2025 | Tirosint, Licart, Tirosint |
| Dexcom, INC. | $69.24 | 2021-2025 | Dexcom G6 Transmitter |
| Bayer Healthcare Pharmaceuticals INC. | $62.84 | 2022-2023 | |
| Ascensia Diabetes Care US INC. | $62.68 | 2019 | |
| Acella Pharmaceuticals, LLC | $52.24 | 2023-2025 | NP Thyroid 60 |
| Intuitive Surgical, INC. | $49.65 | 2019 | |
| Ascendis Pharma Endocrinology INC | $48.02 | 2025 | Yorvipath |
| Beta Bionics, INC. | $41.23 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Kyowa Kirin, INC. | $37.00 | 2023 | Crysvita |
| Novartis Pharmaceuticals Corporation | $36.05 | 2022-2025 | |
| Mannkind Corporation | $35.62 | 2021-2023 | Afrezza |
| Amarin Pharma, INC. | $31.82 | 2019 | |
| Valeritas, INC. | $28.26 | 2019 | |
| Clarus Therapeutics INC. | $23.97 | 2021 | |
| Halozyme INC | $21.89 | 2023 | |
| Sequel Med Tech, LLC | $20.03 | 2025 | Twiist |
| Lifescan, INC. | $18.56 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $18.04 | 2020 | |
| Currax Pharmaceuticals LLC | $17.84 | 2023 | Contrave |
| Ultragenyx Pharmaceutical INC. | $16.59 | 2020 | |
| Almatica Pharma LLC | $15.36 | 2025 | Teriparatide |
| Shire North American Group INC | $14.51 | 2019 | |
| Madrigal Pharmaceuticals | $14.45 | 2025 | Rezdiffra |
| Pfizer INC. | $14.36 | 2019 | |
| Gilead Sciences, INC. | $13.55 | 2019 | |
| Averitas Pharma INC. | $13.55 | 2025 | Qutenza |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $11.56 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$41,358.62 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chi Tang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.